GlassScriptPhysician profile
Phu T Pham
NPI 1669454237
$4,188.75
in general payments reported to CMS, 2019-2025
32 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,519 · 2020: $286 · 2021: $545 · 2022: $266 · 2023: $124 · 2024: $182 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,111.47 | 2019-2020 | |
| Novo Nordisk INC | $858.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $414.16 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $104.94 | 2019-2025 | Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.47 | 2025 | Caplyta |
| Exact Sciences Corporation | $50.09 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.53 | 2020-2022 | |
| Glaxosmithkline, LLC. | $31.84 | 2021-2023 | Arexvy, Shingrix |
| Nevro Corp. | $28.06 | 2022 | |
| Medtronic, INC. | $27.57 | 2023 | Intellis Adaptivestim |
| Pfizer INC. | $27.29 | 2025 | |
| Horizon Therapeutics Plc | $26.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.32 | 2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.08 | 2024 | Jardiance |
| Corium, LLC | $24.93 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.14 | 2019-2021 | |
| Amgen INC. | $23.91 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $23.65 | 2022 | |
| Daiichi Sankyo INC. | $22.40 | 2022 | |
| Abbott Laboratories | $21.93 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $20.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.20 | 2022 | |
| Amarin Pharma, INC. | $17.80 | 2019 | |
| Hologic Sales and Service, LLC | $17.18 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.58 | 2022 | |
| Mylan Specialty L.P. | $16.52 | 2021 | |
| Gilead Sciences, INC. | $15.36 | 2021 | |
| Medtronic USA, INC. | $14.96 | 2019 | |
| Currax Pharmaceuticals LLC | $14.20 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.42 | 2019 | |
| Phadia US INC. | $13.19 | 2024 | Immunocap |
| Genentech USA, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phu Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.